Regeneron and Sanofi announced that a late-stage trial for the blockbuster anti-inflammatory drug Dupixent for patients with chronic spontaneous urticaria (CSU) was halted due to futility.
Novartis and BeiGene bookended 2021 with collaborative deals. In January, Novartis licensed the China-based company’s checkpoint inhibitor, tislelizumab. On December 20, the Swiss pharma giant announced the licensing of the late-stage TIGIT inhibitor ociperlimab to bolster Novartis’ immunotherapy pipeline.
